Abstract

Background
Multistakeholderism as a norm stating that global public issues should be addressed by all those who affect or are affected by this issue, has become increasingly institutionalised in global governance, including the United Nations (UN) system. Despite an increasing body of evidence showing the risks of corporate capture of multistakeholder governance (MSG) and its related inability to deliver effective public health outcomes, this approach is increasingly common. While research shows that industry actors have pushed for MSG, and others have questioned its legitimacy, how MSG is constructed, legitimised and contested by different actors has not been systematically studied. Analysing responses to World Health Organization (WHO) consultations related to non-communicable diseases (NCDs) and associated risk factors, this study examines how actors construct or contest the legitimacy of MSG to address these public health issues.

Results
Our analysis of 135 responses to 10 consultations revealed significant differences in how actors justified or contested MSG. Proponents of MSG, primarily industry-affiliated organisations, often cited industry expertise and resources as key justifications for a multistakeholder approach, in which they invariably included industry as a key stakeholder. Conversely, non-profit and academic respondents often argued against industry inclusion in MSG, referring to conflicts of interest, corporate capture of the policy process and the associated risks that MSG with industry actors poses to democratic and effective policymaking. While actors commonly invoked the same values (e.g., participation, effectiveness, fairness), they interpreted these differently, to argue for or against the inclusion of industry in MSG.

Conclusion
Our findings underscore the contested nature of MSG, with actors calling on similar values and terminology to support fundamentally opposing positions. The ambiguity of concepts like participation, accountability and conflicts of interest may risk creating an opportunity for private sector interests to promote MSG as an ambiguous governance concept to fit their agenda. Given the normative role of WHO and other UN agencies in shaping what is considered ‘good governance’, it is essential for the WHO and other UN agencies to critically examine the evidence on multistakeholder approaches before deciding on its appropriateness and use unambiguous terminology when discussing their interpretation of the approach.
Original languageEnglish
Article number66
JournalGlobalization and Health
Volume21
Issue number1
DOIs
Publication statusPublished - 11 Nov 2025

Data Availability Statement

The data that support the findings of this study are available from public websites of the WHO and respondents. Data related to one consultation is not currently publicly available.

Funding

This research was funded by the University of Bath. AvdA and AG are members of the “Local Health and Global Profits” research consortium (Grant no MR/Y030753/1) which is part of Population Health Improvement UK (PHI-UK), a national research network which works to transform health and reduce inequalities through change at the population level.

FundersFunder number
University of BathMR/Y030753/1

    Keywords

    • Corporate capture
    • Global governance
    • Global health policy
    • Multistakeholder governance

    ASJC Scopus subject areas

    • Health Policy
    • Public Health, Environmental and Occupational Health

    Fingerprint

    Dive into the research topics of 'Constructing and contesting industry’s role in multistakeholder governance: a qualitative analysis of responses to WHO consultations'. Together they form a unique fingerprint.

    Cite this